PharmaCyte Biotech Inc (PMCB)

[rudygerner]

The new IR could prove to be instrumental, and the pre-clinical results for Phase 1 could be the catalyst. The pre-clinical results from TD2 and Dr. Von Hoff are of paramount importance because the slowing of ascites will be a major determining factor for FDA Accelerated Approval from the Phase 1 clinical trial. The new and more capable IR, coupled with explosive good news from TD2 could serve to initiate a major upward shift. The mm's know this, which is why they are currently subduing the pps. Once pre-clinical validation is established, we begin our ascent into the dual clinical trial commencement sometime in 1Q15. As I previously posted, we will likely receive pre-clinical results sometime within the next week, or two. Whatever you do, hold onto your shares and add to your position if possible. The next six months are going to be very interesting!